Aspirin May Fight Cancer — But Not for the Reason You Think
Researchers at Tahoe Therapeutics assembled a 100‑million‑cell dataset to ask whether drugs can push cancer cells back toward a normal gene program. Using this approach, they confirmed known colon‑cancer therapies and discovered that sodium salicylate—aspirin without its acetyl group—reverses cancer‑state signatures better than aspirin itself. Laboratory work shows salicylate activates AMPK, degrades the oncogene c‑MYC, and restores tumor‑suppressive miR‑34 pathways, bypassing the need for COX inhibition. The ALASCCA trial later demonstrated that low‑dose aspirin halves three‑year recurrence in PI3K‑mutated colorectal cancer, prompting NCCN guideline updates.
FDA’s Fiscal Year 2027 Budget Is Chock-Full of Legislative Proposals – Especially on Hatch-Waxman and the BPCIA
The FDA’s FY2027 budget request bundles 27 legislative proposals into its Justification of Estimates for Appropriations Committees, a sharp increase from prior years. Highlights include allowing U.S. generic manufacturers to file Paragraph IV certifications a month earlier, deeming all approved...
WATCH: Former Pfizer Europe Chief Toxicologist Testifies Pfizer Vaccine Should Never Have Been Released, Calls Mass Rollout a “Human Experiment”
In March 2026, a former Pfizer Europe chief toxicologist testified before a German parliamentary committee, alleging that critical safety studies for the Comirnaty COVID‑19 vaccine were skipped. He claimed carcinogenicity tests were omitted, reproductive toxicity data were inadequate, and the...
Weekly Reads: Federal Stem Cell Charges Disappear, SCBEM Ethics, Diet & MYCN Cancer, How to Make a Nose
The article examines the abrupt dismissal of former South Carolina lawmaker Stephen Goldfinch’s federal stem‑cell charge, underscoring the uneven enforcement of unapproved cellular therapies. It contrasts this with a pending federal indictment targeting peptide manufacturers, especially BPC‑157, highlighting regulatory blind...
How Pfizer Created More Depressed People
In the early 1990s Pfizer launched Zoloft and deliberately reshaped public and medical perceptions of depression to expand its market. The company promoted a view that ordinary sadness was a chemical imbalance requiring medication, targeting primary‑care physicians as prescribers. This...
GLP-1 Micro Dosing - Strategies and Tactics?
A Reddit user is experimenting with micro‑dosing GLP‑1 agonists, currently injecting 3 mg tirzepide weekly and planning to use a 7 mg generic oral semaglutide tablet. The goal is to reduce visceral adipose tissue and support cartilage regeneration after knee injections, targeting...
Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus...
Corcept Therapeutics presented final overall survival results from the phase 3 ROSELLA trial, showing that Lifyorli™ (relacorilant) combined with nab‑paclitaxel cuts the risk of death by 35 percent and adds 4.1 months to median survival versus chemotherapy alone. The regimen met both overall...
Girl Mice Grew Balls After a One-Letter DNA Change
Researchers at Bar‑Ilan University introduced a single‑letter mutation into a non‑coding DNA segment of female mice, causing them to develop testes. The alteration targeted a regulatory region previously considered "junk DNA," demonstrating that tiny changes can flip sexual development pathways....
Imeglimin. A New and Novel Drug Thats Better than Metformin
Imeglimin, a novel oral antidiabetic approved in Japan and the EU, improves mitochondrial bioenergetics and reduces HbA1c more effectively than metformin. Its renal excretion bypasses the CYP3A4 pathway, eliminating pharmacokinetic conflicts with rapamycin, an mTOR inhibitor used in longevity protocols....
Influenza Vaccination Reduces Cardiovascular Risk Following Infection
A new Danish register‑based self‑controlled case series spanning 2014‑2025 shows that influenza infection triggers a sharp, short‑lived surge in acute myocardial infarction and stroke, especially within the first three days. Prior influenza vaccination cuts the excess cardiovascular risk dramatically, with...
Why Kidney Disease Innovation Is a Tale of Two Cities — and What It Would Take to Change That with...
John Butler, CEO of Akebia Therapeutics, explained the stark contrast between rapid innovation in rare kidney diseases and the near‑absence of new dialysis therapies, blaming regulatory uncertainty and a Medicare bundle that discourages drug development. FDA clarity on endpoints sparked...
Zeto New Wave EEG System Wins FDA Clearance For At-Home Brain Monitoring
Zeto announced FDA 510(k) clearance for its New Wave EEG system, the company’s third FDA‑approved neuro‑diagnostic platform. The device is a 21‑electrode, gel‑free headset designed for short‑term, up‑to‑2.5‑hour recordings in outpatient clinics and patients’ homes. Integrated with Zeto’s cloud and...
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
A study from Daegu Gyeongbuk Institute of Science and Technology shows that overexpressing the neuropeptide somatostatin (SST) in mice reduces microglial activation, lowers amyloid‑β plaque density, and improves spatial memory in the 5xFAD Alzheimer’s model. In vitro, SST boosted microglial...
FDA Clears Low-Dose MRI Contrast Agent Vueway for Newborns and Infants
The U.S. Food and Drug Administration has granted an expanded indication for Bracco's Vueway (gadopiclenol) injection, allowing its use in neonates and infants for contrast‑enhanced MRI. The macrocyclic agent delivers high‑quality images at half the standard gadolinium dose (0.05 mmol/kg), addressing...
Shooting People In The Head and Heart with mRNA Vaccines, Murder One or Insanity?
A recent blog post dramatizes a WHO‑backed Global Vaccine Data Network (GVDN) study that examined 99 million vaccine recipients across eight countries. The study confirmed strong myocarditis and pericarditis signals after mRNA COVID‑19 vaccines, while Guillain‑Barré syndrome and cerebral venous sinus...
Can Forgotten Biotech Break Out?
The iShares Biotechnology ETF (IBB) surged more than 50% from its April lows to a mid‑January peak, then entered a prolonged sideways phase. Recent price action shows the fund just reclaimed its 50‑day moving average but has yet to breach...
How to Master the Pharmacovigilance System Master File for Inspection Readiness
Mastering the Pharmacovigilance System Master File (PSMF) is essential for inspection readiness, as regulators use it to gauge a company’s PV compliance before any formal interview. In the EU and UK, the PSMF must be supplied within seven days of...
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (Avutometinib Capsules; Defactinib Tablets) in Recurrent Low-Grade Serous...
Verastem Oncology presented two‑year median follow‑up data from its Phase 2 RAMP 201 trial of the AVMAPKI® FAKZYNJA® combination (avutometinib + defactinib) in recurrent low‑grade serous ovarian cancer (LGSOC). The updated analysis confirmed a median duration of response of 31.1 months and a median progression‑free survival...
NVIDIA Just Helped Map 31 Million Protein Complexes and the Health Tech Investment Implications Are Enormous
NVIDIA, DeepMind, EMBL‑EBI and Seoul National University expanded the AlphaFold Protein Structure Database to include 31 million predicted protein complexes—23.4 million homodimers and 7.6 million heterodimers—across 4,777 proteomes. Using H100 DGX Superpod clusters, MMseqs2‑GPU and TensorRT‑accelerated inference, the team generated 1.8 million high‑confidence homodimer...
NPPA Gene Therapy to Encourage Greater Regeneration Following Heart Attack
Researchers at Columbia Engineering have engineered an RNA‑lipid nanoparticle that programs skeletal muscle to secrete a pro‑ANP precursor, which the heart‑specific enzyme Corin converts into active atrial natriuretic peptide. This two‑phase gene‑therapy bypasses the need for direct cardiac drug delivery,...
Cleveland Clinic Catalyzer Program Awards $250K to Quantum Startups
Cleveland Clinic’s Quantum Innovation Catalyzer Program will award up to $250,000, matched with in‑kind resources, to three startups applying quantum computing to health challenges. The selected firms—EntangleBio, Polaris Quantum Biotech, and Singularity Quantum—gain access to IBM’s Quantum System One, the...
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
Revolution Medicines’ daraxonrasib (RMC‑6236) was crowned 2025 Molecule of the Year after winning 50% of community votes. The oral, tri‑complex molecular glue inhibitor uniquely targets the active GTP‑bound state of KRAS, NRAS and HRAS, covering both mutant and wild‑type isoforms....
UK Cancer Trial Targets Difficult-to-Treat Tumours in Children
A new CAR T‑cell immunotherapy trial, called Mighty, will enroll up to 60 children and young adults with hard‑to‑treat solid tumours in the UK and US. The study targets rhabdomyosarcoma, Ewing sarcoma and soft‑tissue sarcoma, cancers that behave differently from...
Ossium Health Hosts Facility Tour and Reception for Indiana Governor Mike Braun and Healthcare Leaders
Ossium Health hosted a facility tour and reception with Indiana Governor Mike Braun, showcasing its 34,000‑square‑foot Indianapolis plant that houses five ISO 7 cleanrooms and a bone‑marrow banking platform. The company has treated 23 patients using organ donor‑derived bone marrow, underscoring...
Vedanta Biosciences Showcases Innovative Work on Its Microbiome-Based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)...
Vedanta Biosciences presented a poster on its eight‑strain consortium VE303 and an oral talk on VE707 at the ESCMID 2026 Congress in Munich. VE303 showed more than an 80% reduction in recurrent Clostridioides difficile infection odds in a Phase 2 trial...
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences will present new pre‑clinical and clinical data on its Pressure Enabled Drug Delivery™ (PEDD) platform at the Society of Interventional Radiology 2026 Annual Scientific Meeting in Toronto. The company’s posters and sessions will cover hepatic tumor penetration...
Thursday Discussion Post
Johns Hopkins Clinical and Translational Research Institute announced a clinical trial for a combined Shigella and ETEC vaccine aimed at preventing traveler’s diarrhea. The study will enroll volunteers for outpatient and inpatient arms, offering compensation of up to $5,100. The...
Bispecific ADCs and the Conditions Nobody Is Talking About
Sidewinder Therapeutics announced a $137 million Series B round to push precision bispecific antibody‑drug conjugates (BspADCs) into clinical trials. The funding follows a prior preview of the emerging bispecific ADC niche at AACR, highlighting a surge of early‑stage programs. While the concept...
Baebies’ Finder Platform Secures Dual FDA Clearance and CLIA Waiver
Baebies announced that its Finder platform has received FDA 510(k) clearance for a Flu A&B/SARS‑CoV‑2 test and a CLIA waiver, making it the first molecular point‑of‑care system with multifunctional capabilities. The cartridge‑based device delivers PCR‑quality results in 15‑20 minutes, enabling...
Pharmaceutical Executive Daily: Shionogi Receives Contract Through BARDA's Project BioShield
Shionogi’s U.S. subsidiary secured a BARDA Project BioShield contract that could total $482 million to develop and manufacture its gram‑negative antibiotic Fetroja, with an initial $119 million funded. The agreement funds a U.S. production facility and expands research against high‑priority biothreat pathogens...
Arg-1 Makes Macrophages More Inflammatory, Impairing Cartilage Regeneration with Age
The study identifies Arginase‑1 (Arg‑1) as a key regulator of age‑dependent macrophage behavior that hampers cartilage regeneration. Single‑cell RNA sequencing shows older animals have fewer anti‑inflammatory macrophage subsets, with Arg‑1 expression declining with age, leading to heightened inflammation. Overexpressing Arg‑1...
How Long-Read Sequencing Is Scaling Beyond the Specialist Lab
Advances in long‑read sequencing accuracy, throughput and cost are moving the technology from niche labs to large‑scale research. PacBio’s HiFi reads now deliver whole‑genome data at a few hundred dollars per sample, enabling thousands of genomes per instrument annually. The...
Landmark Federal Indictment for Pop Peptides Alleged ‘Scheme’ Even as RFK Jr. May Soon Un-Ban Some
A federal grand jury indicted Dr. Justin Watkins, owner of Utah's TruHealth Clinic, for relabeling Chinese‑manufactured peptides and selling them to more than 200 patients without disclosing the source or FDA status. The indictment alleges that the clinic repackaged the...
From Innovation to Adoption: Leadership Perspectives on What Makes Life Science Tools Succeed
Dale Gordon, chair of Abselion’s board, explains that life‑science tools only thrive when they solve a clear, high‑value customer problem, fit seamlessly into existing laboratory workflows, and deliver measurable economic and speed advantages. He stresses that operational robustness, data traceability,...
Relacorilant (CORT125134)
Corcept Therapeutics received FDA approval for relacorilant, branded Lifyorli, in combination with nab‑paclitaxel for platinum‑resistant ovarian cancer. The oral agent is a selective glucocorticoid‑receptor antagonist that blocks cortisol signaling without binding other steroid receptors, differentiating it from older cortisol‑pathway drugs....
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More...
GoodRx announced a partnership with Eli Lilly to offer the newly FDA‑approved oral GLP‑1 drug Foundayo (orforglipron) at a self‑pay price of $149 per month. The platform is also rolling out self‑pay pricing for Lilly’s injectable Zepbound (tirzepatide) KwikPen at $299...
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
Cartography Biosciences announced that Gilead Sciences exercised its first option to exclusively license a novel oncology target identified through Cartography’s ATLAS and SUMMIT single‑cell platforms. The target is part of a multi‑year collaboration aimed at tumor‑selective antigens in triple‑negative breast...
Are Genetically Engineered Humans Coming
CRISPR technology now makes germline editing of human embryos technically feasible, though current U.S. policy blocks federal funding and FDA approval. Private startups are exploring the market despite regulatory uncertainty, and some jurisdictions lack explicit bans. While disease‑preventing edits could...
From Fringe to Formulary: How Integrative Medicine, Peptides, and the D2C Biomarker Stack Are Reshaping the Boundaries of Evidence-Based Care
Integrative health, once a fringe market, now commands a $30 billion out‑of‑pocket industry with 37 % of U.S. adults spending on modalities like acupuncture, functional‑medicine and peptide protocols. Federal agencies are building measurement tools—NIH’s NCCIH $170 M Whole Person Health Index—and the VA’s...
High Dose Influenza Vaccine Correlates with Greater Reduction in Dementia Risk
A retrospective cohort study of U.S. seniors found that receiving a high‑dose inactivated influenza vaccine (H‑IIV) was associated with a significantly lower risk of Alzheimer’s disease compared with the standard‑dose vaccine (S‑IIV). The analysis used claims data from 2014‑2019, covering...
How to Make Cancer Therapies BETter: An Insight Into the Distinct Roles of BET Proteins
A new study from the Max Planck Institute reveals that BET proteins BRD2 and BRD4 play distinct, sequential roles in gene activation, explaining why broad‑spectrum BET inhibitors have shown limited clinical success. BRD4 drives the release of RNA polymerase II,...
Breathing New Life Into Tubercolosis Treatment with Iinhalable Nanomedicine
Scientists at the University of Witwatersrand’s Wits Advanced Drug Delivery Platform have created an inhalable nanocarrier that can encapsulate all four first‑line tuberculosis drugs and release them directly in the lungs. The system bypasses the liver and bloodstream, aiming to...
Octopus-Shaped Nanomachine Reprograms ATP Flow to Starve Cancer Cells
Researchers unveiled an octopus‑shaped nanomachine, HSA‑ABC, that anchors to cancer cell membranes and uses an ATP‑sensing aptamer to trigger photodynamic therapy and rapid doxorubicin delivery. The device creates a self‑amplifying cycle: ATP binding activates a photosensitizer, damaging the membrane, which...
“I Don’t Need Those Pills”—Until the Second Heart Attack
At ACC 2026, researchers unveiled the Ez‑PAVE trial, a multicenter, randomized study of 3,048 South Korean patients with established atherosclerotic cardiovascular disease. The trial compared an ultra‑low LDL‑C target of <40 mg/dL against a conventional target of <70 mg/dL, using statin plus...
Cell-to-Cell Power Grid: How Mitochondrial Transplantation Is Redefining Metabolic Aging and Tissue Rescue
A new comprehensive literature review evaluates mitochondrial transplantation (MTx) and the Drp1 inhibitor Mdivi‑1 as experimental strategies to reverse metabolic aging in diabetic animal models. The analysis highlights how MSC‑derived mitochondria can induce mitophagy, suppress apoptosis, and modulate immune pathways...
Molecular Hydrogen as a Treatment for Chronic Fatigue Syndrome
Molecular hydrogen is emerging as a potential therapy for chronic fatigue syndrome (ME/CFS) by protecting mitochondria from oxidative damage and restoring cellular energy production. Pre‑clinical and early‑stage human trials show hydrogen‑rich water and inhalation improve endurance, lower blood lactate, and...
Tumor-Inspired Microparticles Reprogram Fat Cells and Improve Insulin Sensitivity
Researchers have engineered injectable silica microparticles that mimic the nanoscale surface roughness of invasive cancer cells, stripping away all biological material. When cultured on these tumor‑inspired topographies, mouse adipocytes rapidly lose their mature phenotype, become multipotent stem‑like cells, and exhibit...
Lynavoy (Linerixibat) Wins FDA Approval for Rare Liver Disease After Alfasigma-GSK Licensing Deal
Alfasigma secured FDA approval for Lynavoy (linerixibat), the first U.S. therapy specifically indicated for cholestatic pruritus in primary biliary cholangitis (PBC). The approval follows a March licensing agreement with GSK that could be worth up to $690 million, including a $300 million...
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
Bausch + Lomb received FDA 510(k) clearance for its Bi‑Blade™+ dual‑port vitrectomy cutter and the Adaptive Fluidics update on the Stellaris Elite system. The new cutter operates at 25,000 cuts per minute, a 66% speed boost over the prior model, and delivers a...
VION Biosciences Closes Acquisition of CTL, Strengthening Functional Immune Monitoring Capabilities
VION Biosciences announced the closing of its acquisition of Cellular Technology Limited (CTL), adding ELISPOT and FluoroSpot analyzers, software, consumables, and assay services to its portfolio. The deal enhances VION’s ability to provide functional immune‑monitoring solutions across translational and clinical...
